Table 1. Main characteristics and results of the eligible studies.
|
NSCLC |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
All studies |
Any stage (I–IV) |
Locoregional (I–II) |
Surgical treatment (I–III) |
SCLC |
Carcinoid tumours |
Any histology any stage |
||||||||
| Total | S | Total | S | Total | S | Total | S | Total | S | Total | S | Total | S | |
| Number of studies | 37 (20) | 15 (10) | 10 (5) | 4 (4) | 8 (5) | 3 (2) | 11 (6) | 3 (2) | 1 (1) | 1 (1) | 2 (1) | 2 (1) | 5 (2) | 2 (0) |
NSCLC=non-small-cell lung cancer; SCLC=small-cell lung cancer; S=number of studies identifying Ki-67 positivity as a statistically significant prognostic factor; ()=number of studies evaluable for meta-analysis.